Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P100034/S044

Optune HFE Transducer Array Soft Part Components

Novocure, GmbH · Decision date Apr 9, 2026

FDA DECISIONP100034/S044

What did the FDA decide?

FDA records P100034/S044 as a supplement to PMA P100034, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Apr 9, 2026.

FDA approval order statement

approval for an additional servicing supplier for the soft parts components used in the Optune HFE transducer arrays
Regulatory pathway
PMA supplement
Supplement type
30-Day Notice
Clinical specialty
Neurology
Decision date
Apr 9, 2026
FDA change category
Process Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record

Regulatory record facts

Identifier
P100034/S044
Regulatory pathway
PMA supplement
Product code
NZK
Decision code
OK30
Decision date
Apr 9, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Stimulator, low electric field, tumor treatment.

Product code
NZK
FDA device class
3

For the original device and its historical approval scope, see PMA P100034. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P100034 · Original PMA

    NOVOCURE LTD'S NOVOTTF-100A TREATMENT KIT

  2. P100034/S041 · Related supplement

    Optune Gio - Maxpoint Version 2.0

  3. P100034/S044 received

    Application receipt date recorded by FDA.

  4. P100034/S044 · FDA decision

    30-Day Notice

  5. P100034/S046 · Related supplement

    Optune HFE Transducer Arrays

  6. P100034/S045 · Related supplement

    Novocure GmbHs Optune Gio

Timeline entries are records held by MedtechLedger for P100034. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P100034

Product / regulatory recordCompanyPathwayDecision dateSource
Novocure, GmbHPMA approvalApr 8, 2011FDA
Novocure, GmbHPMA supplementOct 23, 2025FDA
Optune GioP100034/S043
Novocure, GmbHPMA supplementFeb 25, 2026FDA
Optune GioP100034/S042
Novocure, GmbHPMA supplementJun 4, 2026FDA
Novocure, GmbHPMA supplementSep 16, 2026FDA
Novocure, GmbHPMA supplementSep 18, 2026FDA

Explore the linked device profile

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Novocure, GmbH

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
Neuhofstrasse 21, Baar, 6340

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records